Investigating Trends in Quality of Life in Patients with Idiopathic Pulmonary Fibrosis (IPF) Under Treatment with Nintedanib (QUALIFY IPF)

Study identification

• EU PAS number:
  EUPAS25664
• Study ID:
  44734
• Official title and acronym:
  Investigating Trends in Quality of Life in Patients with Idiopathic Pulmonary Fibrosis (IPF) Under Treatment with Nintedanib (QUALIFY IPF)
• DARWIN EU® study:
  No
• Study countries:
  Greece
• Study description:
  Multi-center, non-interventional, prospective cohort study aiming to enroll 120 IPF patients receiving treatment with nintedanib in a consecutive manner from 10-12 reference centers across Greece.
• Study status:
  Ongoing

Study timelines

Date when funding contract was signed

Planned:15/06/2018

Actual:15/06/2018

Study start date

Planned:05/03/2019

Actual:05/03/2019

Date of final study report

Planned:31/12/2023

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

BOEHRINGER INGELHEIM ELLAS SA

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable